To directly address the requirement for PRC2/Ezh2 in ErbB2-driven breast cancer progression, we performed a series of experiments where Ezh2 was ablated or down-regulated in ErbB2+ breast cancer models. Here, ERBB2 is linked to breast carcinoma.